X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA FRESENIUS KABI ONCO. ASTRAZENECA PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 91.9 22.1 415.5% View Chart
P/BV x 13.1 3.1 420.7% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
FRESENIUS KABI ONCO.
Mar-13
ASTRAZENECA PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,285176 730.1%   
Low Rs63479 807.6%   
Sales per share (Unadj.) Rs189.637.7 503.1%  
Earnings per share (Unadj.) Rs-0.25.1 -4.0%  
Cash flow per share (Unadj.) Rs3.86.7 57.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.642.5 161.3%  
Shares outstanding (eoy) m25.00158.23 15.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.13.4 149.9%   
Avg P/E ratio x-4,712.725.0 -18,862.6%  
P/CF ratio (eoy) x249.618.9 1,318.7%  
Price / Book Value ratio x14.03.0 467.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,98820,135 119.1%   
No. of employees `0001.61.2 135.3%   
Total wages/salary Rs m1,605703 228.2%   
Avg. sales/employee Rs Th3,040.25,176.2 58.7%   
Avg. wages/employee Rs Th1,029.2610.4 168.6%   
Avg. net profit/employee Rs Th-3.3699.6 -0.5%   
INCOME DATA
Net Sales Rs m4,7405,963 79.5%  
Other income Rs m9218 511.7%   
Total revenues Rs m4,8325,981 80.8%   
Gross profit Rs m-1301,430 -9.1%  
Depreciation Rs m101258 39.2%   
Interest Rs m0-26 0.0%   
Profit before tax Rs m-1391,216 -11.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m139-68 -204.0%   
Tax Rs m5342 1.5%   
Profit after tax Rs m-5806 -0.6%  
Gross profit margin %-2.724.0 -11.4%  
Effective tax rate %-3.728.1 -13.0%   
Net profit margin %-0.113.5 -0.8%  
BALANCE SHEET DATA
Current assets Rs m2,7265,102 53.4%   
Current liabilities Rs m2,4352,385 102.1%   
Net working cap to sales %6.145.6 13.5%  
Current ratio x1.12.1 52.4%  
Inventory Days Days74150 49.2%  
Debtors Days Days41113 36.0%  
Net fixed assets Rs m1,0355,148 20.1%   
Share capital Rs m50158 31.6%   
"Free" reserves Rs m9426,556 14.4%   
Net worth Rs m1,7166,732 25.5%   
Long term debt Rs m0952 0.0%   
Total assets Rs m4,15610,388 40.0%  
Interest coverage xNM-45.8-  
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.10.6 198.7%   
Return on assets %-0.17.5 -1.6%  
Return on equity %-0.312.0 -2.5%  
Return on capital %014.6 0.0%  
Exports to sales %5.774.5 7.7%   
Imports to sales %6.524.8 26.1%   
Exports (fob) Rs m2704,441 6.1%   
Imports (cif) Rs m3061,477 20.7%   
Fx inflow Rs m3755,298 7.1%   
Fx outflow Rs m4701,772 26.5%   
Net fx Rs m-963,525 -2.7%   
CASH FLOW
From Operations Rs m-81,274 -0.6%  
From Investments Rs m-146-1,204 12.1%  
From Financial Activity Rs m862-196 -439.7%  
Net Cashflow Rs m709-126 -561.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 81.0 92.6%  
Indian inst/Mut Fund % 0.3 0.3 100.0%  
FIIs % 15.7 9.6 163.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 9.1 100.0%  
Shareholders   12,856 42,599 30.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   PANACEA BIOTECH  BIOCON LTD  J.B.CHEMICALS  NATCO PHARMA  AJANTA PHARMA  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 23, 2017 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS